ASH 2011

San Diego, CA—The investigational proteasome inhibitor MLN9708 is the first oral drug in this class to enter clinical trials in multiple myeloma. Although development is still in the early stages, interest in this agent is very high.

San Diego, CA - The final analysis of the pivotal phase 3 VISTA (Velcade as Initial Standard Therapy in Multiple Myeloma) trial, which evaluated a bortezomib-based regimen in treatment-naïve patients with multiple myeloma, upheld the survival benefit seen with bortezomib in previous analyses, investigators reported at the 2011 American Society of Hematology annual meeting.

Results 1 - 2 of 2
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology